BioCentury | Feb 14, 2020

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

Within one month of its stock reaching an all-time high, Innovent priced its second follow-on offering on the Hong Kong exchange early Thursday, raising HK$2.4 billion ($303.2 million) to expand manufacturing capacity in preparation for...
BioCentury | Feb 8, 2020

Skyrizi’s the limit? AbbVie forecasts blockbuster year for psoriasis drug

In newly released guidance Friday, AbbVie projected $1.2 billion in 2020 sales of Skyrizi after the drug far surpassed sales expectations in its first several months on the market. Sales of Skyrizi risankizumab-rzaa climbed to...
BC Extra | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

EMA's CHMP issued a positive opinion for Novartis’ Beovu brolucizumab in its December roundup of opinions, none of which were negative. The agency backed an MAA from Novartis AG (NYSE:NVS; SIX:NOVN) for Beovu to treat...
BC Extra | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being...
BC Extra | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process  Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its...
BC Extra | Nov 26, 2019
Company News

Nov. 26 Company Quick Takes: Kyowa, Ardelyx expand partnership; plus ICER, Celltrion, Asahi-Veloxis and Merck

Kyowa, Ardelyx expand collaboration with new targets and $20M investment  Under an expanded partnership, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will pay Ardelyx Inc. (NASDAQ:ARDX) $10 million in research support over the next two years...
BC Extra | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

Eidos hits new peak on Phase II extension readout in amyloidosis  Eidos Therapeutics Inc. (NASDAQ:EIDX) shares climbed $8.47 (18%) to $55.02, touching an all-time intraday high of $55.25, after the company said results of a...
BC Extra | Nov 18, 2019
Politics & Policy

Warren vows quick executive action to seize pharmaceutical IP

Sen. Elizabeth Warren (D-Mass.) intends to spend three years building support in Congress for a Medicare for All plan, but if elected president will take immediate executive action to reduce drug prices, she said in...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BC Extra | Nov 1, 2019
Company News

Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

Recently launched psoriasis drug Skyrizi exceeded sales expectations for the second quarter in a row, as immunology and hemato-oncology drugs continue to drive AbbVie’s growth ahead of anticipated U.S. biosimilar competition for Humira. Sales of...
Items per page:
1 - 10 of 848